Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27824844 | 1.00 | LMNA (0.48) | LMNANAMPTKCNH2TRPV1KMT2A | |
| SCHEMBL7277525 | 0.93 | TACR1 (0.43) | LMNANAMPTKCNH2TRPV1KMT2A | |
| SCHEMBL8691338 | 0.91 | ELANE (0.46) | LMNANAMPTKCNH2TRPV1KMT2A | |
| SCHEMBL1257864 | 0.91 | LMNA (0.53) | LMNANAMPTKCNH2TRPV1KMT2A | |
| SCHEMBL8010107 | 0.87 | FKBP4 (0.46) | LMNANAMPTKCNH2TRPV1KMT2A | |
| SCHEMBL11435718 | 0.87 | NAMPT (0.48) | LMNANAMPTKCNH2TRPV1KMT2A | |
| SCHEMBL8010157 | 0.86 | KCNH2 (0.54) | KCNH2HTTALDH1A1MAPK1CYP2C9 | |
| SCHEMBL3277774 | 0.85 | FKBP4 (0.57) | KMT2ATACR1 | |
| Dimethyl Sulfoxide SCHEMBL15323267 | 0.85 | TACR1 (0.43) | LMNATRPV1KMT2AMMP2TACR1 | |
| SCHEMBL1295440 | 0.85 | FKBP4 (0.53) | LMNANAMPTKCNH2TRPV1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016120764-A1 | ASPERGILLUS ORYZAE PROLYL ENDOPEPTIDASES AND USE THEREOF IN DEGRADATION OF POLYPEPTIDES | CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (CHUV) (CH) | 2016-08-04 | — | — | WO | disclosed |
| US-8835393-B2 | Inhibitors of IAP | GENENTECH, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120276075-A1 | SYNERGIC ACTION OF A PROLYL PROTEASE AND TRIPEPTIDYL PROTEASES | CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (CHUV) (CH) | 2012-11-01 | — | — | US | disclosed |
| EP-2515932-A2 | SYNERGIC ACTION OF A PROLYL PROTEASE AND TRIPEPTIDYL PROTEASES | Centre Hospitalier Universitaire Vaudois (CHUV) (CH) | 2012-10-31 | — | — | EP | disclosed |
| US-20110269696-A1 | INHIBITORS OF IAPS | GENENTECH INC. (US) | 2011-11-03 | — | — | US | disclosed |
| WO-2011077359-A2 | SYNERGIC ACTION OF A PROLYL PROTEASE AND TRIPEPTIDYL PROTEASES | CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (CHUV) (CH) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269696-A1 | INHIBITORS OF IAPS | XIAP, BIRC5, BIRC3 | LMNA 698/4885NAMPT 3375/4885KCNH2 3202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.